Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 10/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 7/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10432598 | 0.78 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL4833694 | 0.76 | CSNK1D (0.53) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL4286489 | 0.72 | CSNK1D (0.58) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL17610305 | 0.70 | CSNK1D (0.57) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL15478684 | 0.70 | CSNK1D (0.57) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL27463414 | 0.70 | KMT2A (0.36) | KMT2APOLBADORA2AADORA1 | |
| SCHEMBL27446013 | 0.70 | MAPT (0.31) | KMT2AADORA2AADORA1 | |
| SCHEMBL12859266 | 0.69 | CSNK1D (0.55) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL1257163 | 0.69 | CSNK1D (0.51) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 | |
| SCHEMBL22309898 | 0.69 | SLC6A4 (0.50) | CSNK1DCSNK1EMAPK14MAPK11MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | CSNK1D 1185/4885CSNK1E 1190/4885MAPK14 3421/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | CSNK1D 1185/4885CSNK1E 1190/4885MAPK14 3421/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | CSNK1D 1185/4885CSNK1E 1190/4885MAPK14 3421/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | CSNK1D 1181/4885CSNK1E 1351/4885MAPK14 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.